Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Evotec AG ( (EVO) ) is now available.
On 8 January 2026, Evotec SE announced that its Seattle-based subsidiary Just – Evotec Biologics received a new grant from the Gates Foundation to support AI-driven optimization of monoclonal antibodies and other biologics, using its J.MD molecular design suite. The funding will finance ten new J.MD projects over the next three years to enhance manufacturability, stability, pharmacokinetics and other developability attributes of biotherapeutics targeting multiple global health indications, with the aim of lowering costs and expanding access in low- and middle-income countries; the announcement underscores Evotec’s growing role in leveraging advanced biologics platforms for global health applications and extends a collaboration with the foundation that has already yielded multiple cGMP manufacturing campaigns for infectious disease antibodies. Separately, on the same date, Evotec submitted a Notification of Major Holdings to the German financial regulator, indicating ongoing capital markets activity and shareholder structure developments that may be relevant for investors monitoring the company’s ownership dynamics.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a Germany-based life science company focused on drug discovery and development, integrating AI-driven innovation and advanced technologies across small molecules, biologics, cell therapies and related modalities. Through its wholly owned subsidiary Just – Evotec Biologics, the group operates a first-to-industry biologics platform that uses AI/ML-enabled molecular design, continuous manufacturing and process intensification to move biotherapeutics from discovery to commercial launch, with a strong emphasis on improving accessibility and affordability for partners that include major pharma companies, biotechs, academia and global health stakeholders.
Average Trading Volume: 132,531
Technical Sentiment Signal: Sell
Current Market Cap: $1.2B
See more insights into EVO stock on TipRanks’ Stock Analysis page.